• XELL Deutschland
  • XELL English
  • XELL China

Maximizing process yields: Trust Xell with our ideal combination of R&D services!

High-performance cell culture media for the production of monoclonal antibodies – and vaccines or viral vectors for gene therapy applications especially – are more relevant than ever. One efficient approach to increase process yields is to select the most suitable medium – or even better, to utilize a completely customized medium. By leveraging Xell’s long-standing […]


The journey to AAV production in suspension: Scale up your process

Adeno-Associated Viral vectors (AAV) are among the most widely used vectors for gene therapy applications and their importance has become even more evident recently. To support you in your process scale-up, we address questions like “Why should you consider transferring your AAV production from adherent to suspension?” and discuss different case studies (AAV-2 and AAV-8) […]


The key to an easier scale-up: Suspension-adapted cells

Traditional mammalian cell culture is usually anchor-dependent and serum-supplemented, which is directly connected to a series of disadvantages, due to the serum/ animal derived components. In contrast, suspension cultures in animal-derived component free (ADCF) cell culture media have several advantages: reduced lot-to-lot variability of the medium easier scale-up no risk of blood-borne pathogens massively reduced […]